TGC Biomics

Executive Summary

TGC Biomics GmbH is a Berlin-based biotechnology service provider specializing in DNA isolation, PCR amplification, cloning, and synthetic gene construction. Founded in 2017, the company offers a broad range of molecular biology services to academic and industrial clients, with capabilities including nucleic acid extraction from diverse sources, target sequence amplification, and vector cloning. The firm also collaborates with third parties for synthetic gene synthesis, positioning itself as a flexible partner in the genomics and microbiome sectors. While TGC Biomics operates as a private, stage-agnostic entity with no disclosed fundraising or valuation, its service-oriented model generates recurring revenue through project-based contracts. The company's focus on fundamental genetic tools aligns with growing demand for outsourced biotech services, though its lack of proprietary platforms or product pipelines limits scalability. With a lean operation and no disclosed milestones, TGC Biomics presents a low-risk, steady-growth profile in the competitive German biotech ecosystem.

Upcoming Catalysts (preview)

• TBDExpansion of Service Portfolio into Next-Generation Sequencing (NGS)70% success
• TBDStrategic Partnership with Microbiome-Focused Therapeutics Companies50% success
• TBDISO or GMP Certification to Access Regulated Markets60% success